Cargando…

Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma

SIMPLE SUMMARY: Oesophageal adenocarcinomas are a distinct subtype of oesophageal cancer that has an increasing incidence in western countries. As these cancers are often late presenting, patients with locally advanced oesophageal adenocarcinomas are routinely treated with neoadjuvant chemotherapy w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, William, de Jong, Jelske M., van Hillegersberg, Richard, Read, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869950/ https://www.ncbi.nlm.nih.gov/pubmed/35205743 http://dx.doi.org/10.3390/cancers14040996

Ejemplares similares

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer
por: Lang, Cameron C. J., et al.
Publicado: (2022)

Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer
por: Lavery, Anita, et al.
Publicado: (2021)

Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients
por: El Mashed, Shereen, et al.
Publicado: (2022)

Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated?
por: Park, Jin-Soo, et al.
Publicado: (2021)

Prognostic implications of the extent of downstaging after neoadjuvant therapy for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma
por: Kamarajah, Sivesh K, et al.
Publicado: (2023)

Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma
por: Petrillo, A., et al.
Publicado: (2022)

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
por: M. Naeini, Marjan, et al.
Publicado: (2023)

Shrinkage versus fragmentation response in neoadjuvantly treated oesophageal adenocarcinoma: significant prognostic relevance
por: Graham Martinez, Cristina, et al.
Publicado: (2022)

Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma
por: Powell, A. G. M. T., et al.
Publicado: (2020)

Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using (18)F-FDG PET/CT
por: Goense, Lucas, et al.
Publicado: (2018)

Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors
por: Vošmik, Milan, et al.
Publicado: (2021)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours
por: Thomaschewski, Michael, et al.
Publicado: (2018)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma
por: Jain, Anish J., et al.
Publicado: (2023)

Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy
por: Powell, A. G. M. T., et al.
Publicado: (2020)

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma
por: Göbel, Holger H., et al.
Publicado: (2022)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer
por: Vollenbrock, S. E., et al.
Publicado: (2019)

Tonsillar metastasis of oesophageal adenocarcinoma
por: Struijs, Bram, et al.
Publicado: (2007)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
por: Turkington, Richard C, et al.
Publicado: (2019)

Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas
por: Cox, Samantha J., et al.
Publicado: (2017)

Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon
por: Valkema, Maria J, et al.
Publicado: (2023)

Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
por: Moore, Jonathan L., et al.
Publicado: (2023)

Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma
por: Shoucair, Sami, et al.
Publicado: (2022)

The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet‐ring cells, and/or poorly cohesive cells
por: Valkema, Maria J, et al.
Publicado: (2023)

Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies
por: de Klerk, Leonie K., et al.
Publicado: (2021)

A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas
por: Slotta-Huspenina, J, et al.
Publicado: (2013)

Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas
por: Lindblad, M, et al.
Publicado: (2006)

Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: Hagens, E. R. C., et al.
Publicado: (2020)

MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma
por: Bibby, Becky A. S., et al.
Publicado: (2015)

Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
por: Yoon, Han Gyul, et al.
Publicado: (2021)

Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro‐oesophageal junction
por: Christensen, J. F., et al.
Publicado: (2018)

Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer
por: Kauppila, Joonas H., et al.
Publicado: (2018)

Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: de Jongh, M, et al.
Publicado: (2021)

Correction: MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma
Publicado: (2015)

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
por: Gillham, Charles M, et al.
Publicado: (2007)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma
por: Pickering, Oliver J., et al.
Publicado: (2021)

Endoscopic Management of Dysplastic Barrett’s Oesophagus and Early Oesophageal Adenocarcinoma
por: Eusebi, Leonardo Henry, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fqmgpfb4luh0npit912c8a2msk